Page 13 - ITDO_lay_4feb

PolyU – Axis Therapeutics Joint Center for Immunotherapy
Launched to Develop Innovative Cancer Treatments

Date
18 July 2018

Abstract

PolyU joins forces with Axis Therapeutics to foster the research and development of
translational medicine by setting up a Joint Center for Immunotherapy. The Center is set to
conduct collaborative research on cancer immunotherapy, with an aim to develop new cancer
treatments.
A memorandum of understanding (MoU) signing ceremony for setting up the PolyU—Axis
Therapeutics Joint Center for Immunotherapy was held at PolyU campus, signed by Ir Professor
Ping-kong Alexander WAI, Vice President (Research Development) of PolyU; Dr Johnson LAU,
Chairman and CEO of Athenex, Inc.; and Mr YongHui WANG, Chairman and CEO of Xiangxue
Pharmaceutical and CEO of Xiangxue Life Sciences.
In this collaboration, PolyU will provide full support for the research on novel technologies and
genetics models to develop cancer immunotherapy technologies based on TCR-T and CAR-T.

High-impact Collaborative Research Platform 11